GlassScriptPhysician profile
Amelia M Lepi
NPI 1356865034
$3,583.33
in general payments reported to CMS, 2019-2025
30 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $460 · 2023: $712 · 2024: $993 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,839.35 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $993.10 | 2021-2025 | |
| Novo Nordisk INC | $412.79 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $370.44 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.97 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $200.26 | 2022-2025 | Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $190.29 | 2024-2025 | Voquezna |
| Alkermes, INC. | $162.27 | 2021-2025 | Aristada, Vivitrol, Vivitrol |
| Lilly USA, LLC | $113.95 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $101.08 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $93.43 | 2025 | Symbravo, Auvelity |
| Qol Medical, LLC | $77.65 | 2023-2024 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.65 | 2021-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $69.43 | 2022 | |
| Glaxosmithkline, LLC. | $61.22 | 2022-2023 | Bexsero |
| Indivior INC. | $61.03 | 2021-2025 | Sublocade |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $51.94 | 2024-2025 | Edwards Sapien Xt Transcatheter Heart Valve (Thv), Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Exact Sciences Corporation | $48.85 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.34 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $40.13 | 2024-2025 | Veozah |
| Braeburn INC. | $29.65 | 2024-2025 | Brixadi |
| Bayer Healthcare Pharmaceuticals INC. | $27.13 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $25.82 | 2022 | |
| Mylan Specialty L.P. | $21.39 | 2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $17.85 | 2025 | Rexulti |
| Corcept Therapeutics | $16.86 | 2025 | Korlym |
| Cequr Corporation | $16.53 | 2025 | Cequr Simplicity |
| Soleno Therapeutics, INC. | $15.85 | 2025 | Vykat Xr |
| Orexo US, INC. | $14.58 | 2024 | Zubsolv |
| Lundbeck LLC | $14.47 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Lepi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.